Clinical Trial

The Study of ICP-248 in Patients With Mature B-cell Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination Therapy in Patients with Mature B-cell Malignancies.This study consists of two parts: Part 1 dose-finding period and Part 2 dose expansion period.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-02-13; most recent amendment 2025-09-02.
Status change: Not Yet Recruiting → Recruiting 2023-03-30
Trial Details
NCT Number NCT05728658
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Hematological Malignancies
Enrollment 191 participants
Start Date 2023-03-09
Primary Completion 2025-08-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-08